A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer
Abstract Background Medullary Thyroid Carcinoma (MTC) is closely associated with mutations in the RET proto-oncogene, placing the activated RET protein at the center of MTC pathogenesis. Existing therapeutic solutions, primarily tyrosine kinase inhibitors such as selpercatinib, vandetanib, and caboz...
Saved in:
Main Authors: | Tariq Alqahtani, Arwa Alsubait, Meshari Aloumi, Abdulrahman Alamer, Ghala Alomari, Osama I. Alwassil, Ahmad J. Obaidullah, Sahar S. Alghamdi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-024-13345-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients
by: Guenda Di Benedetto, et al.
Published: (2025-01-01) -
A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01) -
Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma
by: Moon Young Oh, et al.
Published: (2024-12-01) -
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01) -
Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review
by: Siyu Lei, et al.
Published: (2024-11-01)